Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Earlier is not necessarily actionable: the clinical dilemma of circulating tumor DNA-detected molecular relapse in resected melanoma

This short commentary (pages 592-593) discusses the clinical dilemma of acting on ctDNA-detected molecular relapse after resection of melanoma. No abstract was available, so no further findings are summarized here.

Melanoma ResearchPubMed 42956181DOI 10.1097/CMR.0000000000001146